She adds, “Odor identification has been identified as a useful screening tool that predicts conversion from mild cognitive ...

Actively Exploring Partnership for Alzheimer’s DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VCNX), a clinical-stage biotechnology ...

Lecanemab, a drug designed to slow the progression of early stage Alzheimer's will not be available to patients in Sweden for ...